With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
As more countries rise out of poverty, CGD’s work in this area focuses on the inequities and emerging problems that jeopardize global health progress.
As more countries rise out of poverty, CGD is focusing on the inequities and emerging problems that jeopardize global health progress: How should governments allocate scarce health budgets rationally? How can global health donors and other development partners advance global health security, pandemic preparedness, and health systems strengthening? What can be done to address health inequities in low- and middle-income countries? What are evidence-informed policies to address market failures that span from early-stage pharmaceutical research and development to supply chain efficiency and ensure health product markets work for the poor?
CGD research helps policymakers build sustainable health systems, respond to shifting realities, and deliver value for money.
Philip Morris International and other cigarette manufacturers are among the most profitable firms in the world, selling the world’s most lethal legal product. They prominently advertise their commitment to corporate social responsibility on everything from child labor to renewable energy. They’ve even conceded that smoking is dangerous and say they are committed to a smoke-free world. But none of these initiatives make up for breaching their most fundamental corporate social responsibility—one defined quite cogently by free-market-advocate Milton Friedman—to pursue their profits “without deception and fraud.”
Rena Eichler, Ruth Levine and the Performance-Based Incentives Working Group
Donor spending on global health has surged, yet for many poor people in developing countries even basic prevention and treatment remain elusive. CGD’s newest book, Performance Incentives for Global Health: Potential and Pitfalls, shows how modest payments in cash or kind can get more health from health care spending. Informed by case studies and the Working Group on Performance-Based Incentives, co-authors Rena Eichler and CGD vice president Ruth Levine tell how to design and implement effective incentive programs—and what to avoid.
Global health action has been remarkably successful at saving lives and preventing illness in many of the world’s poorest countries. This is a key reason that funding for global health initiatives has increased in the last twenty years. Nevertheless, financial support is periodically jeopardized when scandals erupt over allegations of corruption, sometimes halting health programs altogether.
Despite improvements in censuses and household surveys, the building blocks of national statistical systems in sub-Saharan Africa remain weak. Measurement of fundamental statistics such as births and deaths, growth and poverty, taxes and trade, land and the environment, and sickness, schooling, and safety is shaky at best.
This paper focuses on the role that price transparency may play in the efficient and effective procurement of medicines by middle- and low-income countries. Will making prices publicly available make procurement more efficient and cost-effective medicines more accessible? We conclude that transparency of the procurement process significantly lowers costs by encouraging bidders.